Other Names for this Disease
- Pancreatic VIPoma
- Vasoactive intestinal peptide (VIP) tumor
- Vasoactive intestinal peptide-producing tumor
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
On this page
Treatment for VIPoma may include intravenous (IV) fluids to correct dehydration, medications such as octreotide to help control diarrhea, and surgery to remove the tumor. If the tumor has spread (metastasized) to the liver or other tissues, treatment may involve chemotherapy, radiofrequency ablation, or hepatic artery embolization.
Last updated: 3/8/2010
- Stitham SO. VIPoma. MedlinePlus Web site. September 4, 2008; http://www.nlm.nih.gov/medlineplus/ency/article/000228.htm. Accessed 3/8/2010.
- Song S, Shi R, Li B, Liu Y. Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Pancreas. 2009 Oct;38(7):811-4. http://www.ncbi.nlm.nih.gov/pubmed/19657309 .
- Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg. 2008 Feb;12(2):382-93. http://www.ncbi.nlm.nih.gov/pubmed/17510774 .
- Moug SJ, Leen E, Horgan PG, Imrie CW. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology. 2006;6(1-2):155-159 http://www.ncbi.nlm.nih.gov/pubmed/16354964.
- Case CC, Wirfel K, Vassilopoulou-Sellin R. Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report. Med Oncol. 2002;19(3):181-187 http://www.ncbi.nlm.nih.gov/pubmed/12482130.
- ClinicalTrials.gov lists trials that are studying or have studied VIPoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
- Orphanet lists clinical trials, research studies, and patient registries enrolling people with this condition. Click on Orphanet to view the list.
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
(Novartis Pharmaceuticals Corporation)
The FDA has approved this product to be used in this manner.
|Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.|
|More Information about this product||
Drug Information Portal
Medline Plus Health Information